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INTRODUCTION 
Heart disease is the leading cause of death for both men and women in the U.S.[1] Yet, 
current treatment has varying degrees of success. In fact, ten percent of those with heart failure 
find no success with therapy or symptom management and are considered to have advanced heart 
failure.[2] Due to the prevalence and severity of heart disease, research to gain deeper 
understanding and promote opportunities for cardiovascular therapies are highly beneficial.  
Improper calcium ion cycling is often the cause of heart failure.[3] The concentration of 
calcium ions impacts contraction and relaxation therefore investigating cardiac calcium cycling 
is valuable. A small protein in the sarcoplasmic reticulum (SR) membrane, phospholamban 
(PLN), impacts cardiac contractility as it plays a role in calcium ion cycling. Phospholamban is a 
known inhibitor of the sarco/endoplasmic reticulum Ca+2 ATPase pump (SERCA).  Research 
seeks to more fully comprehend the composition, interactions, and physiological role of PLN; as 
well as design and investigate potentially therapeutic mutants of PLN. Mutants of PLN have 
been investigated as a target for gene therapy to prevent and treat heart failure. Ideal therapeutic 
mutants of PLN would modify PLN activity to in turn relieve some inhibition on SERCA. Given 
the current knowledge and revealing the significant physiological role of PLN, continued study 
of PLN is valuable as it will yield a greater understanding of cardiomyopathy, and holds 
cardiovascular therapeutic potential. 
For this project I designed, cloned, expressed, and assessed rational mutants of 
phospholamban with the aim of therapeutic potential. The hope was to answer in part, or in full, 
several questions: 1) How might each of the rationally designed mutants affect the disorder and 
mobility of PLN? 2) Can the PLN mutants be effectively cloned, expressed, and purified? 3) 
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How do the PLN mutants interact with its main regulatory enzymes? 4) Do the PLN mutants 
meet the criteria for a PLN therapeutic mutant design? 
Here, background related to PLN including structure, regulation by phosphorylation, and 
modulation of SERCA is detailed. Predictions and findings on properties and synthesis of 
rationally designed PLN mutants are also presented. Of the four mutants designed, the 
substitution of arginine with glutamic acid at position 14 (R14E), and glutamine substituted with 
glutamic acid at position 26 (Q26E) were able to be cloned, expressed, and purified. Findings 
suggest that R14E and Q26E are predicted to fit three out of the five criteria for PLN therapeutic 
mutant design as minimal change to secondary structure and increased disorder or mobility in 
domain 1a is predicted. Furthermore, this project highlights the usefulness of these 
bioinformatics databases to screen for potential mutants for study. Phospholamban is valuable to 
study and PLN mutants R14E and Q26E are promising for continued analysis to further answer 
the major questions. Continued study of these mutants could offer insight into the interaction 
between SERCA and PLN, and to potential treatments for heart failure.  
BACKGROUND 
Heart Disease and Treatment 
There were over one million hospitalizations for congestive heart failure (CHF) in 2010 
alone, and it is estimated that 5.8 million people in the United States have CHF.[4] Heart failure is 
characterized by an insufficient amount of blood pumped by the heart for the needs of the body. 
The heart compensates for failure in several ways: such as enlarging by stretching or increasing 
muscle mass, and pumping faster. These compensations lead to many of the common symptoms 
of heart failure, including shortness of breath, fluid build-up, and increased heart rate.[2]  
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One of the most common types of CHF is idiopathic dilated cardiomyopathy, which 
affects 40 out of 100,000 in the population.[3]  Idiopathic dilated cardiomyopathy can be caused 
by a specific PLN mutation where arginine at position nine is substituted with cysteine. The 
disease is characterized by left ventricular dilation and systolic dysfunction. The left ventricle 
pumps oxygen rich blood from the atrium to the rest of the body. When the left ventricle is 
enlarged, less blood is able to be pumped, resulting in less volume of oxygenated blood to the 
rest of the body. [2] Systolic dysfunction results in an inability of the ventricles to contract 
normally, thus less volume of blood enters circulation. A decrease in the volume of oxygenated 
blood to the rest of the body can be damaging as it is inadequate for the needs of other organs 
and biological processes.  
 Current prevention and treatment of heart failure as outlined by the American Heart 
Associate include lifestyle changes, medications, and surgery.[2] Depending on the severity of 
heart failure and the damage, these treatments have varying success. Yet, ten percent of those 
with heart failure find no success with therapy or symptom management. 
Due to the prevalence and severity of heart disease, research intended to gain deeper 
understanding and promote opportunities for cardiovascular therapeutic potential is highly 
beneficial. Gene therapy has been proposed as a promising method for the treatment of heart 
failure as it has the potential to affect biological processes impacting heart failure.[5] Gene 
therapy is the use of genes, delivered via a carrier called a vector, to treat or prevent disease.[6] 
The vector containing the therapeutic gene can be delivered intravenously, or directly into tissue. 
Gene therapy either introduces a new gene, or replaces a mutated one with a healthy gene, to 
produce a functional protein as a means to treat or prevent disease.  
Calcium Ion Cycling and SERCA 
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Often, calcium ion handling in heart muscle cells is a cause of heart failure; therefore, 
calcium ion handling is a worthwhile gene therapy target to investigate.[3] Calcium ion cycling is 
crucial to cardiac muscle function as it signals muscle contraction and relaxation. A defect in 
cycling affects the rate and strength of contraction and relaxation. The sarcoplasmic reticulum 
(SR) is a membranous network of tubes surrounding each myofibril, and it stores intracellular 
calcium ions. Calcium ion pumps are located on the SR membrane, allowing for the release and 
re-uptake of calcium ions by the SR. This calcium ion cycling is closely regulated as calcium 
concentration in the cytoplasm of a muscle cell signals either muscle contraction or relaxation.[7]  
The presence of calcium activates contractile proteins, and when the concentration of 
calcium ions in the cytoplasm is high, the calcium ions bind to troponin C of the troponin protein 
complex.[8] When a large amount of calcium, around 1 μM, is present in the cytosol, calcium can 
bind to troponin causing the removal of the tropomyosin blockade, exposing the binding sites for 
the myosin heads on the actin filaments.[9,10] Upon the binding of calcium ions, troponin shifts its 
position, therefore moving the attached protein tropomyosin, which is coiled around the protein 
actin. Before the shift, tropomyosin blocks the myosin binding sites on actin. After the shift, 
which was due to the binding of the calcium ion, the myosin binding site on actin is available 
(Figure 1). The myosin head is then able to bind to the newly exposed sites on actin. Muscle 
contraction occurs as the energy molecule adenosine triphosphate (ATP) forms a bond with 
myosin, causing myosin to release from actin. Then, as ATP is hydrolyzed to adenosine 
diphosphate (ADP) and phosphate, the energy produced bends the myosin protein head back, to 
loosely bind to the next site on actin. As the inorganic phosphate is released, the myosin head 
pushes on actin, providing a power-stroke, and then releases ADP. The cycle can then begin 
again, and continue, with the binding of another ATP molecule. However, as the cytosolic 
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concentration of calcium decreases to around 100nM calcium ions are removed from troponin. 
This allows tropomyosin to bind and cover the myosin binding sites on the actin filaments—and 
relaxation occurs. 
 
Figure 1: Binding of calcium ion to troponin.[11] As calcium ions bind, the myosin binding sites 
previously covered by tropomyosin are exposed allowing for contraction. 
Relaxation occurs by the re-uptake of the calcium ions into the SR by the SERCA pump, 
also referred to as the calcium pump.[12] In Figure 2, SERCA is shown in the SR membrane 
associated with PLN. SERCA pumps two calcium ions from the cytosol into the SR by ATP 
hydrolysis, altering the concentration of calcium in the cytosol, and thus affecting the strength 
and rate of contraction and relaxation.[13] In fact, 75% of the calcium ions are removed from the 
cytosol by SERCA, and 25% are removed by the sodium/calcium exchanger.[14] The inability to 
remove cytosolic calcium ions, such as by one of these pumps in the cell membrane, decreases 
the amount of calcium ions loaded into the SR, resulting in impaired systolic function in 
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subsequent contractions.[5] The SR is the main source of calcium ions for cardiac myocytes. 
Often, a defect in calcium ion cycling is related to an inadequate calcium ion store in the SR.[15] 
With a smaller store of calcium ions to be released for the next contraction, cardiac contractility, 
or the strength of the contraction, is reduced. Reduced cardiac contractility characterizes heart 
failure and as a result, leads to irregular or insufficient contraction of the cardiac muscle. 
Therefore, the activity of SERCA is important to normal cardiac contractility. In fact, studies 
have found that in human heart failure the average activity of SERCA is reduced.[12] 
 
Figure 2: Calcium cycling.[16] Calcium is released by RyR and binds to troponin on the myofibril 
allowing for contraction. Calcium is re-uptaken into the SR by SERCA as regulated by PLN, 
allowing for relaxation. 
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Phospholamban, a Regulator of SERCA 
Since the activity of SERCA is crucial to cardiac contractility, factors that influence the 
activity of SERCA are important to consider. One of the main regulators of SERCA is a small 
protein contained in the SR membrane, phospholamban (PLN) (Figure 3). Phospholamban 
allosterically regulates SERCA, meaning PLN interacts with SERCA at a site other than the 
enzyme active site.[13] Through interaction with PLN the structure of SERCA is altered and this 
change impacts the affinity of SERCA for calcium ions. In turn, the activity of the pump and 
subsequent contraction and relaxation is affected. The change in structure and interactions 
translates to a change in function. The structure-function relationship is key to biological systems 
for several reasons, one being that it allows for regulation.  
 
  
Figure 3: Phospholamban ribbon image.[17] The pentamer of five α-helices is shown in ribbon 
form with each α-helix identified by a different color. 
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The change in interaction between PLN and SERCA is based on the phosphorylation 
state of PLN: whether PLN is phosphorylated or dephosphorylated. Proteins have a hierarchical 
structure that can be altered when a protein is modified, and this change in structure affects the 
function. Phospholamban is regulated by modification with a phosphate group (PO4
-3). The 
enzyme protein kinase A (PKA) phosphorylates, meaning it adds a phosphate group. When a 
phosphate group is added it affects the structure of the protein due to changes in interactions, 
charge and/or spatial arrangement. Specifically, when PLN is phosphorylated the change in 
structure relieves inhibition on SERCA, allowing for more calcium ions to be pumped into the 
SR. Therefore, cardiac contractility is increased because the removal of the calcium ions from 
the cytosol into the SR increases the available calcium ion store for the next cardiac cycle. 
When the phosphate group is removed by the enzyme protein-phosphotase-1 (PP1), the 
structure of PLN changes. Dephosphorylated PLN inhibits the activity of SERCA, decreasing the 
number of calcium ions pumped into the SR, resulting in a decrease in the strength of subsequent 
contractions because of the decreased availability of calcium ions.[18] Phospholamban interacts 
and allosterically regulates SERCA by impacting the affinity of SERCA for calcium ions, and as 
a result, affecting cardiac contractility.  
Studies support the link between PLN inhibition of SERCA and heart failure. In human 
heart failure it has been found that SERCA levels are typically low, resulting in a high ratio of 
PLN to SERCA.[19] The higher the ratio, the greater the inhibition on SERCA, causing lower 
calcium affinity. Less calcium affinity results in less calcium reuptake into the SR; so less 
calcium is available for the next contraction. Additionally, researchers have found significantly 
decreased amounts of phosphorylated PLN in patients with heart failure. [19] Consequently, 
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higher amounts of dephosphorylated PLN are present, inhibiting SERCA. Clearly, PLN is related 
to heart failure by its modulation of SERCA activity. 
With a link to heart failure, PLN has and continues to be studied to learn more about the 
interaction with SERCA in hopes to identify potential therapeutic options. The structure of 
proteins can be manipulated to observe the functional impact of the change and to offer further 
insight into the nature of the interaction or function. One way the structure can be altered is by 
changing a specific amino acid using site-directed mutagenesis. The resulting DNA is a mutant, 
and the resulting protein is different. Studies altering the primary structure of a protein, the 
amino acid sequence, of PLN and observing the physiological impact have been performed. The 
findings support the impact of PLN on cardiac contractility. In fact, studies of super-inhibitory 
mutants of PLN in mouse models suggest that PLN impairs cardiac function.[12] Furthermore, 
mice deficient in PLN were studied and showed increased contraction and relaxation function, as 
well as an increase in the affinity of SERCA for calcium ions.[20] PLN is clearly linked to cardiac 
contractility and heart failure. 
Several PLN mutants are notable for having an impact on cardiac contractility. For 
instance, Iwanaga et al. have executed studies on a PLN mutant where serine at position 16 has 
been substituted with glutamic acid (S16E), which mimics the phosphorylated state and therefore 
does not inhibit SERCA.[5] It is thought that in the S16E PLN mutant, part of the cytoplasmic 
domain unfolds to a similar degree that PLN unfolds when phosphorylated, therefore relieving 
inhibition on SERCA.[21] Also, this mutant likely competes with wild-type PLN for interaction 
with SERCA. Use of S16E PLN in rat models showed improved left ventricular function in rats 
with myocardial infarction.[5] Competition and assay data utilizing cardiac cells support these 
findings showing that PLN mutant S16E can compete with wild-type PLN. Therefore, S16E 
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PLN has an ability to interact with SERCA, and alter its activity.[21] Furthermore, S16E PLN 
administered in gene therapy has shown to reverse heart failure in sheep.[22] In fact, adeno-
associated-virus-mediated gene therapy to overexpress SERCA or inhibit PLN continue to be 
investigated in in-vivo and clinical trials in humans.[9] These results suggest that the success 
found in the animal models to prevent heart failure and heart failure progression could be 
effective to prevent or treat heart failure in humans via gene therapy.  
A second noteworthy PLN mutant is a human genetic mutation where arginine at position 
nine is replaced by cysteine (R9C) and is known to cause heart failure. It is thought that this 
mutant has an inability to be phosphorylated at serine 16, therefore SERCA inhibition cannot be 
relieved, likely contributing to a decrease in contractility and therefore heart failure 
progression.[5] These research findings on PLN mutants, among others, demonstrate the ability to 
affect the function of SERCA through the dynamics of PLN.[13]  
Assessing the outcome of altering the primary structure of the protein offers insight as to 
which amino acids are important to the function and interactions of the protein. Therefore, 
rationally designed PLN mutants are useful to investigate for potential therapeutic use. Since 
phosphorylated PLN relieves inhibition on SERCA allowing improved cardiac contractility, 
mutants are often designed to mimic the phosphorylated state, which is characterized by 
possession of increased structural dynamics. 
Structure and Properties of Phospholamban 
Phospholamban is a relatively small protein: around 6 kDa and composed of fifty-two 
amino acids in its monomeric form.[7] The structure of PLN is shown in Figure 4 and the 
sequence of amino acids for wild-type phospholamban is shown in Figure 5. It is a 
transmembrane protein of the SR, meaning it is bound in the SR membrane, of cardiac and 
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smooth muscle. The SR is one of two membranes surrounding each myofibril and is involved in 
muscle contraction and relaxation as it serves as a calcium ion store.[23] Proteins, calcium pumps, 
and calcium channels compose the SR.[24]  
 
Figure 4: Structure of PLN illustrating spatial arrangement of amino acids.[31] 
 
Figure 5: Amino acid sequence of wild-type phospholamban (WT PLN). 
Phospholamban is classified as a type II membrane protein as it is anchored to the SR 
membrane via its C-terminus.[25] This largely hydrophobic protein has a secondary structure 
   Poss 15 
 
consisting of a left-handed coiled-coil. Phospholamban is a monomer when dephosphorylated 
yet, when phosphorylated five monomers aggregate to form a 30 kDa pentamer (Figure 3). It 
possesses a high level of symmetry and is composed of five trans-membrane α-helices connected 
to one cytoplasmic α-helix via -sheets.  
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Figure 6: Phospholamban amino acid diagram.[19] Each amino acid residue in the primary 
sequence of PLN is depicted. The amino acid number and the three domains are indicated on the 
left-hand side. The two blue residues indicate phosphorylation sites (S16 and T17). 
Three distinct domains comprise a phospholamban monomer; each with unique 
properties contributing to the function of the protein. Figure 6 provides a schematic of these 
domains—Ia, Ib, and II. The first domain is a hydrophilic region at the amino terminal, labeled 
“Ia” in Figure 6, and is known as the cytoplasmic domain.[24] This area, consisting of 22 amino 
acids is highly charged as it is composed of mostly basic residues. The cytoplasmic domain 
contains the two phosphorylation sites, serine at position 16 and threonine at 17. Phosphorylation 
and dephosphorylation of these residues allows for the regulation of PLN activity. Both serine 16 
and threonine 17 are oriented outward in 3-dimensional space, facilitating phosphorylation. The 
secondary structure of the cytoplasmic domain is an amphipathic helix, with the hydrophilic 
residues on one face, and the hydrophobic residues on the other face—this arrangement is known 
to be important for interactions and order. [26] 
The next domain is the juxtamembrane region, labeled “Ib” in Figure 6. The 
juxtamembrane region includes the amino acids between proline 21 and lysine 27. One notable 
aspect is the presence of three glutamine residues, with the polar hydrophilic R groups oriented 
inside the helix.[24] Another significant feature of the juxta-membrane region is proline at 
location 21, as this outward facing residue acts as a hinge and allows a shape change when PLN 
is phosphorylated at serine 16 and threonine 17.  
The last domain is the oligomer at the carboxylic acid terminal, labeled “II” in Figure 6. 
This region is largely hydrophobic as the twenty-five amino acids are integrated into the SR 
membrane. [7] The overall hydrophobicity allows for this part of the protein to span the 
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hydrophobic membrane. This region contains three cysteine residues. Cysteine possesses a 
unique ability to form a disulfide bond via the covalent linkage between its thiol group and the 
thiol group of another cysteine. Formation of disulfide bonds increase stability of the protein.  
Another aspect of the structure of PLN to note is the amino acid at the C-terminus, 
leucine 52, is charged and actually extends into the inside of the SR.[24] In addition, the 3-
dimensional structural model of PLN illustrates a pattern in the charge on the side of the alpha-
helix of each monomer. The positively charged residues, including three arginine and a lysine, 
and the phosphorylation sites, serine and threonine, are mostly located on the same side of the α-
helix.   
Regulation of Phospholamban by Phosphorylation 
The activity of PLN depends on its phosphorylation state. There are two important 
phosphorylation sites: one located at serine 16 and the other at threonine 17.[24] Both of these 
residues are located in the cytoplasmic domain and are facing outward on the α-helix for easy 
access for phosphorylation by globular kinases. When PLN is dephosphorylated it exists as a 
monomer and is associated with SERCA (Figure 7). Interaction between PLN and SERCA 
decreases SERCA’s affinity for calcium ions, therefore inhibiting its function. [7] Therefore, 
when PLN is dephosphorylated, cardiac contractility decreases. 
However, when PLN is phosphorylated, SERCA inhibition is relived. Five monomers of 
phosphorylated PLN may aggregate to form a pentamer upon phosphorylation (Figure 7).[16] 
However, there is debate on whether or not PLN completely dissociates from SERCA upon 
phosphorylation.[26] The result is an increased affinity of SERCA for calcium ions, therefore 
more calcium ions are pumped back into the SR. Consequently, more calcium ions are available 
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for the next contraction—allowing the increased cardiac contractility. Typically, about 50% of 
PLN is phosphorylated at any point in time.[12] 
 
Figure 7: The structural effect of phosphorylation of phospholamban.[16] The left side of the 
graphic depicts dephosphorylated phospholamban, in its monomeric form, inhibiting SERCA. On 
the right side, phospholamban is phosphorylated, resulting in aggregation of five PLN monomers 
to form a pentamer, relieving inhibition of SERCA. 
Phosphorylation site serine 16 is phosphorylated by cAMP-dependent protein kinase 
(PKA) and threonine 17 is phosphorylated by Ca+2-CAM –dependent kinase (CaMKII).[7] 
Studies have demonstrated that serine 16 must be phosphorylated before threonine 17 can be 
phosphorylated.[18] Conversely, phospholamban can be dephosphorylated at these sites by protein 
phosphatase 1 (PP1) and small heat shock protein 20.[16]  
 One way phosphorylation is initiated is through a cascade of events beginning, with β-
adrenergic activation (Figure 8). Several signals ultimately lead to the phosphorylation of PLN 
and the subsequent increase in active transport of calcium by SERCA. First, a -agonist, such as 
adrenaline is released in response to stress. [18] The -adrenergic agonist activates -adrenergic 
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receptors on the cell membrane of a muscle cell. The signal is transduced via G-proteins to 
stimulate the secondary messenger, adenylate cyclase, activity, producing cAMP. Presence of 
cAMP activates PKA and CaMKII, both enzymes that phosphorylate the proteins of the SR, and 
thus, PLN.[9,10] This results in an increase in cardiac output. 
 
Figure 8: Mechanism of phosphorylation initiation by -adrenergic agonist.[18] The release of a 
-agonist begins a signal cascade resulting in the phosphorylation of PLN (labeled PLB in 
image) causing an increase in the rate of cell contraction and relaxation. 
Phosphorylated and dephosphorylated PLN differ in structure in the degree of folding and 
unfolding.[26] When PLN is phosphorylated an order-disorder transition occurs.[13] Disorder is the 
lack of pattern or regularity in structure of the protein, such as the helix. Phosphorylation of PLN 
results in a negatively charged cytoplasmic domain, causing the helix to unwind. Specifically, 
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phosphorylation at serine 16 causes unfolding of the cytoplasmic region.[27] Regions of PLN that 
fold and unfold are regions Ia, specifically amino acids 1-16, which is part of the cytoplasmic 
domain, and Ib, amino acids 23-30, which is part of the trans-membrane domain. The 
conformational changes disrupt the PLN-SERCA interaction, decreasing PLN activity and 
relieving SERCA inhibition.[13] 
 If PLN is significantly or permanently dephosphorylated, or over expressed, 
hypocontractility can result.[19] Hypophosphorylation of PLN has been linked to dilated 
cardiomyopathy.[9] When PLN is dephosphorylated it inhibits SERCA activity, reducing calcium 
ion affinity and thus decreasing the calcium ion reuptake into the SR. This results in less calcium 
in the SR, impairing the next contraction and contributing to heart failure. Reduced contractility 
decreases blood flow, which can be damaging to cells.   
Several therapeutic approaches to heart failure by modifying PLN could be taken with an 
overall goal to relieve SERCA inhibition and to increase cardiac contractility. These could 
include decreasing PLN expression, increasing phosphorylated PLN, inhibiting PLN-SERCA 
interaction, or designing a PLN mutant without function to compete with functional PLN.[13] 
Decreasing PLN activity via inducing phosphorylation is currently being studied due to the 
potential to treat heart failure.[19]  
Criteria for Phospholamban Therapeutic Mutants 
 Tuning the structural dynamics of PLN has great therapeutic potential and criteria for 
designing PLN mutants has been outlined.[28, 29] First, as discussed, increased structural dynamics 
of PLN to mimic phosphorylated PLN is important. A mutant resembling phosphorylated PLN 
has the potential to have the effect of phosphorylated PLN, alleviating SERCA inhibition. 
Second, mutant PLN must be able to bind to SERCA in the same way as wild-type PLN. This is 
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important as the mutant PLN must be able to interact with SERCA to have potential to regulate 
SERCA activity. Additionally, this will allow mutant PLN to compete with WT PLN. Another 
aspect to consider when designing a therapeutic mutant of PLN is its ability to be 
phosphorylated. By preserving the ability to be phosphorylated it could be useful to allow for 
normal post-translational control. Additionally, the PLN mutant must result in a decreased 
inhibition of SERCA. The aim of therapeutic PLN is to relieve, at least some, inhibition on 
SERCA to allow more calcium ions to be pumped and stored to improve subsequent 
contractility. Last, an inability to be dephosphorylated efficiently is an aspect to consider as 
dephosphorylated PLN inhibits SERCA. Therefore, it would be beneficial to have more PLN 
phosphorylated.  
Project Overview 
Using this information, four rationally designed PLN mutants were designed, and 
predications about their impact on PLN were made. Then, bioinformatics databases were used to 
predicted secondary structure, hydropathicity, and disorder. Next, polymerase chain reaction site-
directed mutagenesis was used to clone the mutants, and the sequence was confirmed with 
Sanger DNA Sequencing. Then, BL21 E. coli cells were used to express the mutant proteins 
which were purified by affinity chromatography.  
RATIONALLY DESIGNED PHOSPHOLAMBAN MUTANTS AND HYPOTHESES  
Glutamine at Position 5 Substituted with Arginine (Q5R) 
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PLN mutant Q5R alters the charge in domain 1a. A change in charge in the cytoplasmic 
region is thought to disrupt PLN inhibitory function.[30] The change is from a polar, uncharged 
amino acid, to a positively charged amino acid. This could result in more interaction with the 
hydrophilic solution and less with the hydrophobic membrane—which could increase the 
flexibility of domain 1a. It is not likely mutant Q5R will affect V4 but it could hydrogen bond 
with Y6 or E2, and repel R9 (Figure 4). Additionally, this substitution results in a change in size 
as arginine is larger than glutamine, potentially causing further structural irregularity.  
Glutamine at Position 5 Substituted with Isoleucine (Q5I) 
 
Mutant PLN Q5I was selected as the change from the polar to the hydrophobic residue 
will likely disrupt the domain 1a helix, and thus PLN inhibitory function. The interactions 
between residues will change as this mutation replaces a polar residue for a hydrophobic one. 
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This change likely will result in disruption of the amphipathic helix because of the change in 
hydropathicity. Therefore, this mutant may mimic the pseudo-phosphorylated state because 
research has demonstrated that the cytoplasmic helix of PLN is disrupted when PLN is 
phosphorylated.[32] Given the change to a hydrophobic residue at position 5, the mutant PLN may 
interact with the membrane more, increasing mobility and altering which face of the helix this 
residue is located. Also, this Q5I may interact or with V4, and repel E2, according to Figure 4. 
Additionally, Q5I would be interesting to compare and contrast with Q5R because the former is 
hydrophobic and the latter is hydrophilic.  
Lysine at Position 3 Substituted with Glutamic Acid/Arginine at Position 14 Substituted with 
Glutamic Acid (K3E/R14E) 
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Studies measuring the affinity of SERCA for calcium ions have shown that charged and 
hydrophobic amino acids from glutamine at position two to isoleucine at position 18 are 
mutation sensitive in affecting the affinity of SERCA for calcium ions.[32] Furthermore, K3 and 
R14 have been identified as residues that not only interact with SERCA, but play a role in the 
inhibition of SERCA. Therefore, changing two charged residues likely will impact the affinity of 
SERCA for calcium ions. In fact, previous physiological studies of cardiac myocytes with 
K3E/R14E mutant showed a 45% increase in affinity of SERCA for calcium ions.[33] 
Furthermore, changing the charge will alter the electrostatic interactions and likely cause 
irregularity in the helix, which could mimic phosphorylation. Also, it is important to note that a 
mutation in this area likely has an impact on the ability of PLN to be phosphorylated by PKA 
because R14 is contained in the minimum recognition sequence for PKA. Therefore, it is 
important to learn more about this mutant. As the project progressed mutant R14E as a single 
mutant was focused on, which alone is a useful mutation and location for investigation. In fact, 
research has demonstrated that R14 deletion leads to dilated cardiomyopathy, providing support 
for the importance of this residue in SERCA regulation.[34] 
Glutamine at Position 26 Substituted with Glutamic Acid (Q26E) 
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Residue 26 is a valuable place to investigate the effect of mutants as it swings away 
during phosphorylation.[35] Therefore, Q26 does not interact with SERCA when PLN is 
phosphorylated as the hydrogen bond between Arg324 of SERCA and Q26 of PLN is broken. 
This has been demonstrated as mutant Q26A results in the loss of PLN function, also suggesting 
the importance of the glutamine side chain for PLN inhibition.[30] Additionally, it is likely that 
residue 26 can impact the flexibility and mobility of PLN as it is near the P21 hinge. Therefore, 
changing from a polar to a charged amino acid likely will impact the mobility of PLN. The 
interaction with SERCA via hydrogen bonding may be altered due to this substitution, 
potentially relieving inhibition.  
METHODS 
Notes 
Monomeric AFA PLN was utilized as the double stranded DNA in PCR vs. the 
pentameric WT PLN. The cysteines at locations 36, 41, and 46, are substituted with alanine, 
phenylalanine, and alanine respectively, in order to simplify the conditions and render PLN in its 
monomeric form for study (Figure 9). AFA PLN is suitable for this study as calcium ion activity 
assays demonstrate no significant difference in activity between WT PLN and AFA PLN.[36]  
 
Figure 9: AFA PLN amino acid sequence. 
Rationally Designing Therapeutic PLN Mutants  
Due to the typical varying success in PCR, four mutants were designed—hoping at least 
one mutant would be successfully cloned. Four PLN mutants to further investigate for 
therapeutic consideration were carefully designed, and their potential impact on PLN was 
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hypothesized. While designing mutants, the five criteria for therapeutic mutant design were kept 
in mind: increased structural dynamics to mimic phosphorylated PLN, an ability to bind to 
SERCA the same as wild-type PLN, an ability to be phosphorylated, decreased inhibition of 
SERCA, and an inability to be dephosphorylated efficiently. Since other successful mutants 
mimic the phosphorylated state of PLN, the mutants rationally designed for this project also 
focused on achieving a pseudo-phosphorylated state. Therefore, like the phosphorylated state, the 
mutants were aimed at altering the structural dynamics—which can be done by altering the net 
charge to disrupt the helix of domain 1a. Also, a change in the hinge region of the 
juxtamembrane domain was considered in hopes to increase mobility. Additionally, it was hoped 
to balance changing the disorder and mobility yet, a minimal change in secondary structure so 
the mutants would still be able to interact with the main PLN regulatory enzymes. 
Bioinformatics Analysis 
 Secondary structure, disorder, and hydropathicity were determined to be the three most 
important properties to assess via bioinformatics databases. These three properties encompass the 
key aspects of the criteria for a PLN therapeutic mutant design. Therefore, secondary structure, 
hydropathicity, and disorder likely will offer insight into whether or not the mutant exhibits a 
pseud-phosphorylated state. The amount of change in the secondary structure is helpful to predict 
if there is a chance the mutant will be able to interact with the main regulatory enzymes. The 
degree of disorder, or the regularity of the helix, will enable a reasonable prediction of whether 
or not the mutant causes a disruption of the tertiary structure, and thus altering the dynamics. 
Hydropathicity is important to assess as a change could cause more interaction with the solvent 
or the membrane depending on the change—which would in turn impact the dynamics of PLN.  
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The bioinformatics tools were found and selected via searching and reviewing available 
databases. Secondary structure was analyzed by the Jpred3 database.[37] Hydropathcity was 
predicted using the peptide property calculator provided on the Innovagen website.[38] The 
disorder was predicted by DisEMBLE.[39] database. For each, the desired sequence of amino 
acids was entered and processed to obtain the predictions 
Mutagenic Primer Design 
Mutant DNA primers to be used in PCR site-directed mutagenesis were designed for each 
of the four rationally designed PLN mutants. Guidelines as outlined by the QuikChange II Site-
Directed Mutagenesis Kit were followed. These guidelines included designing a primer between 
25 and 45 bases in length, 10 to 15 bases on each side of the desired mutation, minimum guanine 
and cytosine base content of 40%, and a melting temperature of greater or equal to 78⁰C. Melting 
temperature was estimated using 




Where N is the total number of bases, and the %mismatch is the number of bases that changed, 
over the total number of bases. Different primers were measured against the criteria until the best 
fit was found for each mutant. The complementary base sequence was also determined, and both 
the forward and reverse sequences were ordered and obtained from Integrated DNA 
Technologies. 
Cloning: Polymerase Chain Reaction Site-Directed Mutagenesis 
Polymerase chain reaction (PCR) site-directed mutagenesis was used to attempt to clone 
the mutants. DNA mutant primers were obtained from Integrated DNA Technologies and each 
was diluted to 50μM with DI water. Then, a 1:5 dilution using 5μM of each solution was 
completed, resulting in a final concentration of 100ng/μL. Each reaction was prepared in a 
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separate micro-centrifuge tube, adding the reagents in the following order: deuterium-depleted 
water (40μL), reaction buffer (5μL), double stranded DNA (2μL, 100ng/μL), forward primer 
(1μL, 100ng/μL), reverse primer (1μL100ng/μL), dNTP (1μL). A corresponding control reaction 
for each mutation was prepared in a separate micro-centrifuge tube, adding reagents in the 
following order: deuterium-depleted water (42μL), reaction buffer (5μL), forward primer (1μL, 
100ng/ μL), reverse primer (1μL100ng/ μL), dNTP (1μL). Next, the enzyme, Pfultra DNA 
polymerase was added (1μL, 2.5U/μL). The reactions were placed in the thermal cycler and 
cycled once at 95⁰C for 30s, and five times through the following cycle: 95⁰C for 30s, 55⁰C for 
60 s, 68⁰C for 60s per kilo-base of plasmid. After the cycles were complete, of DpnI restriction 
enzyme (1μL,10U/μL) was added to each reaction and the reactions were incubated at 37⁰C for 
60m. Next, gel electrophoresis in a 1% weight/volume agarose gel was ran for 60m at 100 volts 
to check the reaction. Samples ran were composed of the reaction (20μL) and ethidium bromide 
for stain (5μL). Once complete, the gel was imaged with UV light. 
PCR Purification 
The GeneJET PCR Purification kit and instructions were followed. A 1:1 volume of 
binding buffer (30μL) was added to the reaction (30μL) and mixed. The mixture was transferred 
to a purification column placed in a micro-centrifuge tube, centrifuged for 30-60s, and the flow-
through was discarded. Wash buffer (700μL) was added and the reaction was again centrifuged 
for 30-60s, discarding the flow-through. The reaction was centrifuged for another 60s. Next, the 
purification column was transferred to a fresh 1.5mL micro-centrifuge tube and elution buffer 
(50μL) was added. The reaction was centrifuged for 60s and the flow-through was stored in a 
micro-centrifuge tube the refrigerator.  
Transformation DH5-α E. coli with PCR Amplified DNA 
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DH5α E. coli (50μL) were thawed and aliquoted into micro-centrifuge tubes. Each 
purified PCR reaction (10-15μL) was transferred into separate micro-centrifuge tube containing 
the cells, using sterile technique. Sterile technique includes performing the transfer in proximity 
of a lit Busen burner. The mixture was incubated on ice for 30m. Then, the reaction was heat 
shocked in a water bath for 45s at 42⁰C to enable the DNA to be up-taken by the E. coli cells. 
Using sterile technique, super optimal broth medium (500μL) was added to the reaction and the 
reaction was incubated with shaking at 37⁰C for one hour. The reaction was centrifuged for 2m, 
most of the supernatant was removed, and then the pellet was re-suspended. The mixture was 
pipetted onto a sterile agar plate, under sterile conditions. The plate was incubated at 37⁰C 
overnight and then observed for colony growth. Colonies that were present were inoculated by 
growing the cells in a liquid broth media (LB) (5mL) overnight. Both a positive control with 
pUC18, and a negative control, were made for a standard of comparison. The plasmids contained 
a gene for ampicillin resistance and for maltose binding protein (MBP). (Heart Disease Fact 
Sheet, 2013) 
Plasmid Purification 
The GeneJET Plasmid Mini Prep Kit instructions were followed to purify the expressed 
plasmid. The solution containing LB and the colony grown overnight was transferred into an 
eppendorf tube and centrifuged for 1m. This was repeated until all of the solution was 
transferred. Then, the pellet was resuspended with resuspension solution (250μL), mixed well, 
and vortexed. Next, lysis solution (250μL) was added and the tube was inverted 4-6 times to mix 
thoroughly. Then, neutralization solution (350μL) was added and the tube was inverted 4-6 times 
to mix. The solution was centrifuged for 5m, forming a white pellet. The supernatant was 
transferred to the GeneJET spin column, centrifuged for 60s, and the flow through was 
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discarded. Next, wash solution (500μL) was added, the solution was centrifuged for 30-60s, and 
the flow through was discarded—this was repeated twice. To remove all excess wash buffer the 
solution was centrifuged for another 60s. The column was transferred to a clean 1.5mL micro-
centrifuge tube. Then elution buffer (50μL) was carefully added and the solution was incubated 
for 2m at room temperature, then centrifuged for 2m. The plasmid DNA was stored in the micro-
centrifuge tube at -20⁰C. 
Quantification of Plasmid 
 UV-vis spectroscopy was used to measure the absorbance of the 1:11 diluted sample at 
260nm. Using Beer’s law A = εcl—where A is the absorbance, ε is the molar absorptivity 
constant, l is the path length, and c is the concentration—the concentration of the sample can be 
calculated. The extinction coefficient for double stranded DNA is 0.02 M-1 cm-1. The samples 
with the known concentration were sent for Sanger DNA sequencing at the University of 
Minnesota. The sample included plasmid (5µL), primer (4µL), and water (3µL). 
Transformation of BL21 E. coli with Plasmid 
BL21 E. coli cells (50μL) were thawed and aliquot into micro-centrifuge tubes. The 
purified plasmid (100ng) was transferred into the micro-centrifuge tube containing the cells, 
using sterile technique. The mixture was incubated on ice for 30m. Then, the reaction was heat 
shocked in the water bath for 45s at 42⁰C to enable the plasmid to be up-taken by the E. coli 
cells. Using sterile technique, super optimal broth medium (500μL) was added to the reaction. 
The reaction was incubated with shaking at 37⁰C for 1h. The micro-centrifuge tube was 
centrifuged for 2m, most of the supernatant was removed, and the pellet was re-suspended. The 
mixture was pipetted onto a sterile agar plate, using sterile technique. The plate was incubated at 
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37⁰C overnight and then observed for colony growth. Colonies that were present were inoculated 
by growing the cells in LB (5mL) overnight. 
Protein Expression 
 The colony in LB media was mixed using sterile technique with autoclaved DI water 
(400mL), 5x LB (100mL), glucose (10mL), vitamin cocktail[40] (5mL), mineral cocktail[40] 
(2.5mL), and ampicillin (500µL). The vitamin cocktail[40] contains calcium pentothenate 
(1mg/L), biotin (1mg/L), folic acid (1mg/L), niacinamide (1mg/L), and pyridoxal phosphate 
(1mg/L). The mineral cocktail[40] is composed of 6 mg/L CaCl2 (6 mg/L), FeSO4 (6 mg/L), 
MnCl2 (1 mg/L), CoCl2 (0.8 mg/L), ZnSO4 (0.7 mg/L), CuCl2 (0.3mg/L), H3BO3 (0.02 mg/L), 
(NH4)6MO7O24 (0.25 mg/L), EDTA (5 mg/L). The solution was placed in the shaker and 
incubated at 37⁰C to grow the cells. The optical density at 600nm was checked using the 
Spectrophotometer to measure the progress of the reaction just under 2h and the reaction was 
allowed to proceed until an optical density of about one was reached, which was achieved at 3.5 
hours. At this time, the cells were induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) 
promoter (1 M) to induce transcription. The cells were incubated for 4.5 hours to allow for 
protein expression, then they were harvested by separation using centrifugation. 
Protein Purification 
 PLB AFA-MBP lysis buffer was made containing phosphate buffered saline (PBS 
500mL), lysozyme (20mg), 100% glycerol (2.5mL), triton-X (2.5mL), dithiothreitol (DTT 50µL, 
1M), leupeptin (25µL, 10ng/mL in dd water), phenylmethylsulfonyl fluoride (PMSF, 2.5mL, 
17.4mg/mL), and pepstantin A (250µL, 1mg/mL in ethanol). The lysis buffer was added to the 
cells, vortexed, and mixed well. The mixture was then blended for several minutes with a hand 
blender, and sonicated for 25m with an interval of 2s. Next, the solution was centrifuged at 
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12,000 RPM for 20m at 4⁰C. Meanwhile, an affinity column with amylose resin (25mL) and was 
washed with 3x the volume of water (75mL), and 2 times the volume of PBS (50mL) to 
equilibrate. Then, the solution was poured over the column. The column was washed with PBS, 
and then eluted with maltose, PBS, and TEV protease to elute MBP-PLN from the column. 
Samples of the supernatant, flow-through, wash, and elution were kept and run on an SDS PAGE 
gel for 35m at 60 mA. The gel was placed in trichloroacetic acid for 10m when it was poured off. 
The gel was stained with coomassie brilliant blue dye and rocked for 10m. Methanol and acetic 
acid were used to de-stain the gel overnight. 
Concentrating Protein Sample 
 The elution sample containing the protein was concentrated using a 10kDa filter in a 
stirred ultrafiltration cell with nitrogen gas until the sample was concentrated to a total volume of 




Secondary Structure: Jpred3.[37] 
In comparison of the secondary structure as predicated by Jpred3, no significant changes 
in the secondary structure or solvent accessibility are observed between each mutant and wild-
type PLN (Figure 10). The results show the secondary structure at each residue. In A) of figure 
10, the two distinct helices connected by a random coil are observed in each sequence similar as 
in wild-type PLN. Also, the prediction of burial with 25% solvent accessibility (Figure 10B) and 
with 5% solvent accessibility (Figure 10C) are similar between each mutant and wild-type PLN. 
These results illustrate predicted minimal, non-significant change in the secondary structure.  
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Figure 10: Secondary structure prediction and prediction of burial at each residue for WT PLN 
and each mutant by Jpred3 Database.[37] 
Hydropathicity Analysis: Innovagen AB.[38] 
 Figure 11 shows the hydropathicity plot at each residue for wild-type PLN (A) and for 
each rationally designed PLN mutant (B-E). For mutant PLN Q5R (Figure 12B), both the wild-
type and the mutant amino acid are hydrophilic, yet there is a change from a polar, slightly 
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hydrophilic glutamine, to a basic, charged, very hydrophilic arginine residue.  Residue five for 
mutant Q5I (C) changes from a polar, slightly hydrophilic glutamine to a aliphatic and 
hydrophobic isoleucine—a more significant change. The double mutation K3E/R14E (D) shows 
a change at both residue three and residue 14 from basic and hydrophilic, lysine and arginine, to 
acidic and hydrophilic, glutamic acid. While these positions remained charged with the mutation, 
the charge is positive in wild-type PLN, but negative in this mutant at locations three and 14. 
Last, PLN mutant Q26E (E) is a mutation from a polar, slightly hydrophilic glutamine residue, to 
a charged, acidic, more hydrophilic glutamic acid. 
 




Figure 11: Comparison of Hydropathicity at Each Residue as Predicted by Innovagen AB. [38] 
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Further analysis of the hydropathicity of wild-type PLN and each PLN mutant is shown 
in figures 12 and 13. No significant difference was observed in the isoelectric point or net charge 
at pH 7 when comparing each Q5R PLN and Q5I PLN to wild-type PLN. The isoelectric point is 
just above 11, and the net charge at pH 7 is around three. Minimal predicted change in the 
isoelectric point and net charge at pH 7 was predicted between Q26E PLN and wild-type PLN. 
Mutant PLN Q26E is predicted to have a slightly lower isoelectric point, 10.38 vs. 11.22, and 
lower net charge at pH 7, two vs. three. PLN double mutant K3E/R14E demonstrated the greatest 
predicted change in isoelectric point and net charge at pH 7 compared to wild-type PLN. This 
mutant is predicted to have a significantly lower isoelectric point, 4.73 vs. 11.22, and lower net 
charge at pH 7, minus one vs. three. 
 
Protein Isoelectric Point Net Charge at pH 7 
WT PLN 11.22 3 
Q5R PLN 11.83 4 
Q5I PLN 11.22 3 
K3E/R14E PLN 4.73 -1 
Q26E PLN 10.38 2 
 
Figure 12: Comparison of isoelectric point and net charge for WT PLN and PLN mutants as 
predicted by Innovagen AB.[38] 




Figure 13: Graphical comparison of isoelectric point and net charge for WT PLN and PLN 
mutants from Innovagen AB[38] data.    
DisEMBLE.[39] 
DisEMBLE is a database predicting the disorder of a protein based on an entered amino 
acid sequence. Two types of disorder are predicted: “loops”, and “hot loops.” Loops illustrates 
the predicted level of disorder based on where loops are present. This is significant because loops 
are the only areas where protein disorder exists, however, loops are not necessarily disordered. If 
loops are not disordered, they are ordered areas with either an alpha helix or beta-strand 
secondary structure. Hot Loops predicts loops with a high degree of mobility as loops that are 
highly dynamic exhibit disorder.  
Disorder is exhibited in domain 1a, specifically between residues 15 and 22. Both 
























Net Charge at pH 7
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upon phosphorylation, are in this range of predicted disorder (Figure 14 and 15). Furthermore, 
proline 21, which is believed to pivot like a hinge in wild-type phospholamban, and therefore is 
highly dynamic, is part of this high disorder range as predicted by DisEMBLE. This is also 
consistent with the secondary structure prediction by Jpred, which illustrates loops in this same 
region. 
The Loops graph (Figure 14) shows that PLN mutant K3E/R14E is predicted to exhibit 
the greatest increase in disorder compared to wild-type PLN. PLN mutant Q26E is predicted to 
possess very similar disorder to that of wild-type PLN. Surprisingly, Loops has predicted that 
PLN mutant Q5I likely will have a decrease in disorder compared to wild-type PLN. 
 Hot loops prediction (Figure 15) illustrates a likely increase in structural dynamics for 
PLN mutants Q5R and Q26E. Double mutant K3E/R14E has been predicted by this method to 
have slightly less mobility compared to wild-type PLN. Additionally, wild-type PLN has a high 
probability of disorder from residues 10-20, while mutants Q5R, Q5I, and Q26E have this hot 
loops region expanded, beginning at residue one.  
 In both types of prediction, Loops and Hot Loops, the differences between wild-type 
PLN and a mutant are most apparent at the peak of disorder. 
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Figure 14: The Loops graph shows the probability of disorder as predicted by DisEMBLE.[39] 
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Figure 15: The Hot Loops graph illustrates the probability of mobility as predicted by 
DisEMBLE.[39] 
Base Sequence of Designed Primers 
Each letter represents a nucleic acid base: A-adenine, T-thiamine, C-cytosine, G-guanine.  
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Figure 16: PLN Mutant Designed Primer Base Sequences. 
Gel Images after PCR 
Figures 17 and 18 show an image of the gel ran after the completion of PCR for each 
designed PLN mutant, and a respective control. After PCR, the reaction was treated with the 
restriction enzyme Dpn-I. Dpn-I is a restriction enzyme that cleaves only methylated DNA, such 
as that produced by the E. coli. However, the recombinant DNA synthesized by PCR is not 
methylated, and therefore would not be cleaved. Therefore, the methylated DNA would be in 
fragments and travel farther on the gel than the uncut recombinant DNA. If any mutated DNA is 
present, a band that has travelled not as far as the digested product would be expected.  
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Samples showing two bands in the gel, which suggest a successful PCR, were purified to 
rid of remaining double stranded DNA. For the Q26E PLN reaction in figure 17 two bands are 
present, illustrating PCR product. The K3E PLN reaction also was potentially a successful PCR 
as there is a smeared band between the well and the digested product band. Some DNA remained 
in the well for both K3E and Q26E, which possibly could be product. Both were treated as 
successful PCR and the process was then continued with transformation.  
 
Figure 17: Gel image showing PCR product for Q26E and potentially for K3E. 
Figure 18 is a gel image illustrating a successful PCR for Q26E PLN and R14E PLN, and 
a likely successful PC for K3E PLN. A second band is present for mutants Q26E PLN and R14E 
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PLN indicating digested DNA. The reaction lane for K3E PLN show a smeared band, suggesting 
the PCR might have worked.  
 
Figure 18: Gel image showing PCR product for R14E and Q26E  
Successful Transformation of DH5-α E. coli with PCR Amplified DNA 
 For a successful transformation the expected result would be the growth of colonies on 
the agar plate. Figure 19 is an image of a successful transformation of mutant PLN Q26E into 
DH5-α E. coli  as colonies grew. Mutant PLN R14E was also successfully transformed to DH5-α 
E. coli. However, K3E PLN was not successfully transformed. Given the success of mutant 
Q26E and R14E these two were focused on for the remainder of the laboratory study. 
 




Figure 19: Colony growth of DH5-α E. coli containing Q26E PLN plasmid. 
Quantification of Plasmid 
Purified plasmids were quantified using UV-vis spectroscopy to measure absorbance at 
260nm, and calculated the concentration using Beer’s Law.  




R14E 0.0662 36.41 
 
Figure 20: R14E quantification data 
 
Sequencing Data 
 The results of Sanger sequencing are below in figure 21, and the mutations are 
highlighted in yellow.  
   Poss 45 
 
 
Figure 21: Amino Acid Sequence for Transformed Samples 
Each letter represents an amino acid. AFA-PLN was successfully cloned as the sequence 
matches that of wild-type PLN exactly, except where cysteine substitutions were expected. Both 
R14E and Q26E were compared for changes in the amino acid sequent to the AFA PLN 
sequence. Mutated R14E PLN was also successfully cloned as the sequence shows a substitution 
of glutamic acid at location 14 for arginine. Additionally, mutant Q26E PLN shows a 
substitution in the sequence of glutamic acid at position 26, and therefore was successfully 
cloned. 
Purification by Affinity Column  
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Figure 22: SDS-PAGE gel image for Q26E affinity chromatography  
 
Figure 23: SDS-PAGE gel image for R14E affinity chromatography 
Figures 22 and 23 shows the results of the Q26E and R14E SDS-PAGE gels run after the 
respective affinity columns. In each gel there is a single band in the elution column, representing 
the desired mutant PLN protein fused to MBP. Figure 22 demonstrate the presence of the protein 
band in the elution, representing the PLN-MBP protein, in the supernatant, but not in the flow-
though. There are corresponding bands the post-induction lane because the protein would begin 
to be expressed. There is also a band present in the pre-induction lane. Comparing the elution 
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band to the molecular marker in Figure 23 shows the eluted protein is around 50kDa, which is 
the molecular weight of PLN-MBP. 
DISCUSSION 
 Through this research, the predicted secondary structure, hydropathicity, and disorder of 
each of rationally designed phospholamban mutants were analyzed. Additionally, two of these 
mutants, Q26E and R14E, were successfully cloned and expressed. These mutants have been 
purified with affinity chromatography and they are ready for final isolation, gel assays, and 
further assessment. Originally, R14E was designed as part of a double mutant, K3E/R14E, 
however, due to the timeline and interest in further processes beyond PCR, it was decided to 
pursue study of the single R14E mutant. 
 The bioinformatics analysis provided helpful insight into potential properties of each of 
the rationally designed mutants. Results of this analysis offered information to make a general 
comparison to the five criteria for rationally designed therapeutic PLN mutants. Jpred3[37] 
seemed to be an accurate bioinformatics tool as it showed two helices connected by a loop in WT 
PLN, which is supported by literature. Secondary structure analysis by Jpred3[37] suggests that 
each of these PLN mutants will retain their ability to bind SERCA, as minimal change to 
secondary structure was observed. An ability to bind to SERCA is important for the mutant to 
have an impact on SERCA affinity, or to potentially compete with wild-type PLN.  
 The Innovagen AB Hydropathicity[38] analysis was also an accurate model as it illustrates 
the known amphipathic helix pattern and showed the correct local changes in charge due to 
substitution. The amphipathic helix pattern can be seen by the hydropathicity switches between 
hydrophobic and hydrophilic every three to four residues. The plot illustrates the localized 
change based on each mutation, and the point amino acid substitution was represented in the 
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correct location in each diagram. Specifically, mutant K3E/R14E showed the largest deviation 
from WT PLN with a lower pKa value; therefore, the carboxylic acid in the R group would be 
deprotonated at biological pH. Prior to the mutation, the R group consists of a positive amino 
group at biological pH. Therefore, this change in charge from negative to positive likely will 
disrupt interactions and the helical pattern, leading to disorder in the structure. Increased disorder 
has the potential to mimic the phosphorylated state of PLN, which is the desired state as it 
relieves SERCA inhibition. 
Disorder is important to assess in PLN mutants as it appears that the success of 
therapeutic PLN mutant S16E is largely in part to the increased structural dynamics exhibiting 
pseudo-phosphorylation, thus relieving SERCA inhibition.[21] Analysis by DisEMBLE[39] 
appears to be a valuable and accurate tool to predict disorder as the result showed an accurate 
disorder prediction for wild-type PLN as supported by literature. Increased structural dynamics 
are predicted in the known loop region, residues 10-20, for wild-type PLN.  
As hypothesized, the double mutant, K3E/R14E is predicted to exhibit an increase in 
disorder (Figure 15). In fact, K3E/R14E is predicted to have the largest increase in disorder of 
the mutants here. PLN mutant Q26E however, showed similar disorder to WT PLN. Yet, in 
comparing the predicted mobility in the hot loops graph, PLN mutant Q26E showed an increase 
in structural dynamics in the loop region, as hypothesized. Since residue 26 is quite close to the 
hinge residue, number 21, it is likely that a change at position 26 will have an impact on the 
mobility due to proximity to residue 21. Additionally, Q26 is thought to swing away during 
phosphorylation; the substitution may result in an ability to swing more freely, potentially 
mimicking the phosphorylated state.[13] While further study was not pursued because of the lack 
of PCR success, Q5R is an interesting mutant for continued study as it is predicted to exhibit an 
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increase in mobility—which was hypothesized and predicted by DisEMBLE.[39] Mutant 
K3E/R14E is predicted to exhibit a slight decrease in mobility. With a change from positive to 
negative charge at two residues in domain 1a, the substituted residues likely may interact with 
amino acids which it previously repelled, potentially resulting in stiffness and a decrease in 
mobility. However, K3E/R14 still appears useful for further study because of the significant 
predicted increase in disorder. These findings are significant as increased disorder and increased 
mobility as predicted here is thought to mimic the phosphorylated state of PLN, which would 
relieve SERCA inhibition and is a desired criteria for therapeutic PLN mutant design. 
Polymerase chain reaction can be a tricky procedure to have success with, even when 
being very careful and following the procedure accurately. This is likely why some, but not all, 
of the PCRs here worked. Also, PCR success attests to the quality of primer design. 
As the PCR gels in figures 18 and 19 show, the bands were not always clear. For this 
reason, PCR purification was used before transformation—which seemed to improve the success 
of transformation. Like the PCR’s, not all transformations were successful, so it was quite 
rewarding to transform two mutants.  
While it was not expected to see a band for the elution protein in the pre-induction lane, 
there are two possible reasons accounting for this. The elution protein, PLN-MBP is 48kDa, 
which is near the average size for proteins, 50kDa. Therefore, it would not be unlikely that there 
is an endogenous protein of this molecular weight appearing in the pre-induction lane. 
Additionally, due to the consistency of the samples before put on the column, this particular gel 
is difficult to run, which could have affected the bands visible in the pre-induction lane. Overall, 
it does offer helpful and accurate information on the presence of the elution protein. Only one, 
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clear, band is visible in the elution column—supporting the expression and purification of the 
desired mutant protein. 
The successful PCR and transformation of R14E and Q26E, as confirmed by sequencing 
data, is a promising result for further study of each of these mutants. It is possible to clone, 
transform, and express PLN mutants R14E and Q26E as confirmed by the affinity SDS PAGE 
gels (Figures 22 and 23). In fact, these mutants are the first successful mutants cloned and 
expressed in the last year in the biochemistry lab at St. Catherine University. Furthermore, these 
mutants possess properties predicted to fit three of the five criteria for PLN therapeutic mutant 
design as assessed thus far. Both PLN mutants demonstrated minimal change to the secondary 
structure, increase in disorder or mobility, and potential to be phosphorylated by PKA.  
One of the goals in designing mutants for this project was to balance making enough 
change to affect the function of PLN, but not too much to inhibit interaction with SERCA or the 
main regulatory enzymes. Minimal change in the secondary structure is thought to be important 
for retaining the ability to interact with SERCA and the main regulatory enzymes of PLN, thus 
preserving some modulation of activity. On the other hand, increased disorder and mobility is 
thought to reduce or relieve PLN inhibition on SERCA. Both of the expressed mutants R14E and 
Q26E appear to achieve this balance as assessed thus far.   
Mutant PLN Q26E preserves the availability of residue 16 to be phosphorylated, 
maintaining some biological control of the system. While it seems unlikely that mutant R14E 
may retain the ability to be phosphorylated by PKA because residue 14 is contained in the 
minimum recognition sequence, there is a possibility that it may. Preliminary studies suggest that 
R14Del does retained the ability to be phosphorylated at S16, however, very slowly.[41] 
Therefore, changing the residue at position 14 may still allow for phosphorylation by PKA at 
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S16. Additionally, these observations support that mutated peptide sequences of PLN as opposed 
to the whole protein also retain the ability to be phosphorylated slowly. The ability to be 
phosphorylated more slowly could be a desirable trait to still allow modulation of activity, but to 
still reduce the inhibition on SERCA.  
CONCLUSION  
 Through this project, four PLN mutants were designed, and four questions were asked 
about these mutants—including effect on disorder and mobility; ability to be cloned, expressed, 
and purified; interaction with regulatory enzymes; and fit compared to the five criteria for PLN 
therapeutic mutant design. It was hypothesized that each mutant would retain a similar secondary 
structure, exhibit increased disorder or mobility, and that at least one mutant would be able to be 
cloned, expressed, and purified. Bioinformatics data analysis of secondary structure, 
hydropathicity, and disorder; PCR-site-directed mutagenesis; transformation of and expression 
with E. coli cells, were used to provide information and results for each question. 
Bioinformatics analysis predicts each of the mutants will exhibit minimal to no change in 
secondary structure, as hypothesized, suggesting the ability to still interact with main regulatory 
enzymes and with SERCA. Mutants R14E and Q26E emerged as valuable not only because they 
are predicted by DisEMBLE[39] to exhibit increased disorder or mobility compared to WT PLN, 
but because they were each cloned, expressed, and purified. The other mutants, with the 
exception of Q5R, generally are predicted to possess similar or decreased disorder or mobility 
compared to WT PLN. In future related projects, these selected bioinformatics databases and 
properties for assessment could be useful to analyze a wide range of mutants in order to narrow 
down the options of potential mutants to pursue further study with in lab.  
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Through this project, rationally designed PLN mutants were assessed via bioinformatics 
and laboratory study. Three of the initial questions asked, number one, two, and four, were 
answered at least in part. Insight was provided to: 1) How might each of the rationally designed 
mutants affect the disorder and mobility of PLN? According to the bioinformatics results, the 
disorder or mobility of R14E and Q26E is predicted to increase. The following question was also 
answered: 2) Can the PLN mutants be effectively cloned, expressed, and purified? Both R14E 
and Q26E were effectively cloned, expressed, and purified. And last, predictions regarding the 
question four were assessed: 4) Do the PLN mutants meet the criteria for a PLN therapeutic 
mutant design? These two mutants, R14E and Q26E are predicted to meet three of the five 
criteria for PLN therapeutic mutant design. 
As a result, these two mutants appear promising to pursue further research with. Both the 
R14E and Q26E mutants have been expressed by BL21 E. coli cells, purified with affinity 
chromatography, concentrated, and are ready for final isolation and further study. Additional 
analysis can seek to assess the interaction between each mutant and the main PLN regulatory 
enzymes. Assessment of the interaction and impact of these mutants on the affinity of SERCA 
for calcium ions is also an important area for future study. In addition, the mutant can further, 
and more closely, be compared against the therapeutic PLN mutant criteria. Further assessment 
of the impact and interaction of each of these two mutants with SERCA could offer insight into 
PLN and SERCA’s role and relation to heart failure; as well as provide potential targets for gene 
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